Physician profile
Charles E Armstrong
NPI 1255743548
$643.65
in general payments reported to CMS, 2019-2025
13 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $52.75 · 2021: $35.72 · 2022: $14.37 · 2023: $36.67 · 2024: $54.03 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $226.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $235.97 | 2019-2020 | |
| Abbott Laboratories | $87.76 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $54.64 | 2025 | Dexcom G6 Transmitter |
| Viiv Healthcare Company | $47.06 | 2021-2025 | Apretude, Cabenuva |
| Merck Sharp & Dohme LLC | $42.82 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $38.06 | 2019 | |
| Janssen Biotech, INC. | $32.59 | 2019 | |
| Boston Scientific Corporation | $21.42 | 2025 | Watchman Flx |
| Verrica Pharmaceuticals INC. | $19.79 | 2024 | Ycanth |
| Theratechnologies INC. | $17.39 | 2019 | |
| Pfizer INC. | $16.97 | 2025 | |
| Glaxosmithkline, LLC. | $14.90 | 2023 | Shingrix, Arexvy |
| Novo Nordisk INC | $14.28 | 2024 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Armstrong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.